PORCILIS EPL is used For the active immunisation of pigs against reproductive problems associated with parvovirus, erysipelas and Leptospira serovars:
- To reduce clinical signs (skin lesions and fever) of swine erysipelas caused by Erysipelothrix rhusiopathiae, serotypes 1 and 2.
- To reduce transplacental infection, viral load and foetal mortality caused by porcine parvovirus.
- To reduce clinical signs (increase of body temperature and reduction in feed intake or activity), infection and bacterial excretion caused by Leptospira interrogans serogroup Canicola serovar Canicola.
- To reduce clinical signs (increase of body temperature and reduction in feed intake or activity), severity of infection and foetal mortality caused by L. interrogans serogroup Pomona serovar Pomona.
- To reduce infection caused by L. interrogans serogroup Icterohaemorrhagiae serovars Copenhageni and Icterohaemorrhagiae, L. interrogans serogroup Australis serovar Bratislava, L. kirschneri serogroup Grippotyphosa serovars Grippotyphosa and Bananal/ Liangguang, L. weilii serogroup Tarassovi serovar Vughia and L. borgpetersenii serogroup Tarassovi serovar Tarassovi.
COMPOSITION OF PORCILIS EPL
| Active ingredient | Quantity per 2 ml dose |
|---|---|
| E. rhusiopathiae, serotype 2 (strain M2) | ≥ 1 ppd1 |
| Porcine parvovirus (strain 014) | ≥ 130 U2 |
| L. interrogans serogroup Canicola serovar Portland-Vere (strain Ca-12-000) | ≥ 2 816 U2 |
| L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni (strain Ic-02-001) | ≥ 210 U2 |
| L. interrogans serogroup Australis serovar Bratislava (strain As-05-073) | ≥ 1 310 U2 |
| L. kirschneri serogroup Grippotyphosa serovar Dadas (strain Gr-01-005) | ≥ 648 U2 |
| L. interrogans serogroup Pomona serovar Pomona (strain Po-01-000) | ≥ 166 U2 |
| L. santarosai serogroup Tarassovi serovar Gatuni (strain S1148/02) | ≥ 276 U2 |
1 Pig protective dose as compared to a reference preparation known to be protective in pigs.
2 As determined in the in vitro antigenic mass ELISA potency test.
The vaccine contains 150 mg dl-α-tocopheryl acetate as an adjuvant and formaldehyde as a preservative.
DIRECTIONS FOR USE – USE ONLY AS DIRECTED
- Before use allow the vaccine to reach room temperature.
- Porcilis® EPL is administered intramuscularly.
DOSAGE AND ADMINISTRATION OF PORCILIS EPL
Administer a single dose of 2 ml per pig via intramuscular injection.
Check out the Vaccination schedule – Click Here
VACCINATION SCHEME FOR PORCILIS EPL
Basic vaccination scheme for PORCILIS EPL
Pigs which have not yet been vaccinated should be given a primary injection 6 to 8 weeks before the expected date of insemination and a booster injection 4 weeks later.
Revaccination for PORCILIS EPL
A single revaccination with Porcilis® EPL should be given once a year. Six months post each vaccination with Porcilis® EPL, a single revaccination with an Erysipelothrix rhusiopathiae containing product should be given to maintain immunity against Erysipelothrix rhusiopathiae. In case of known infection pressure with L. interrogans serogroup Australis, a single revaccination with Porcilis® EPL should be given every 6 months, as it is unknown if or for how long the duration of immunity for this serogroup persists beyond 6 months.
STORAGE
- Store in the dark between 2 °C and 8 °C.
- Shelf-life after first opening the container: 10 hours.
WITHDRAWAL PERIOD FOR PORCILIS EPL
21 days.
PRESENTATION
100 ml.
